These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 30196070)

  • 1. Pathophysiology and inhibition of IL-23 signaling in psoriatic arthritis: A molecular insight.
    Nguyen CT; Bloch Y; Składanowska K; Savvides SN; Adamopoulos IE
    Clin Immunol; 2019 Sep; 206():15-22. PubMed ID: 30196070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-12 and interleukin-23 inhibition in psoriatic arthritis.
    Johnsson HJ; McInnes IB
    Clin Exp Rheumatol; 2015; 33(5 Suppl 93):S115-8. PubMed ID: 26471946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological and synthetic target DMARDs in psoriatic arthritis.
    Silvagni E; Bortoluzzi A; Ciancio G; Govoni M
    Pharmacol Res; 2019 Nov; 149():104473. PubMed ID: 31585178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy.
    Deepak P; Loftus EV
    Drug Des Devel Ther; 2016; 10():3685-3698. PubMed ID: 27956825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of psoriasis and psoriatic arthritis.
    Papoutsaki M; Costanzo A
    BioDrugs; 2013 Jan; 27 Suppl 1():3-12. PubMed ID: 23990277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remission, low disease activity and improvement of pain and function in psoriatic arthritis patients treated with IL-12/23 and IL-17 inhibitors. A multicenter prospective study.
    Perrotta FM; Delle Sedie A; Scriffignano S; Volpe P; Cordisco E; Milano N; Gabini M; Lubrano E
    Reumatismo; 2020 Apr; 72(1):52-59. PubMed ID: 32292021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety of ustekinumab for the treatment of psoriatic arthritis.
    López-Ferrer A; Laiz A; Puig L
    Expert Opin Drug Saf; 2017 Jun; 16(6):733-742. PubMed ID: 28441904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of ustekinumab in the treatment of psoriatic arthritis.
    Roberts J; O'Rielly DD; Rahman P
    Immunotherapy; 2018 Apr; 10(5):361-372. PubMed ID: 29439608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.
    Vu TT; Gooderham M; Papp K
    Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1423-1433. PubMed ID: 27690669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Psoriasis Treatment Pipeline: An Overview and Update.
    Hawkes JE; Al-Saedy M; Bouché N; Al-Saedy S; Drew DT; Song EJ
    Dermatol Clin; 2024 Jul; 42(3):365-375. PubMed ID: 38796268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The new era for the treatment of psoriasis and psoriatic arthritis: perspectives and validated strategies.
    Novelli L; Chimenti MS; Chiricozzi A; Perricone R
    Autoimmun Rev; 2014 Jan; 13(1):64-9. PubMed ID: 24021172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis.
    Alunno A; Carubbi F; Cafaro G; Pucci G; Battista F; Bartoloni E; Giacomelli R; Schillaci G; Gerli R
    Expert Opin Biol Ther; 2015; 15(12):1727-37. PubMed ID: 26653110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ustekinumab for the treatment of psoriasis and psoriatic arthritis: a drug evaluation and literature review.
    Thibodaux RJ; Triche MW; Espinoza LR
    Expert Opin Biol Ther; 2018 Jul; 18(7):821-827. PubMed ID: 29949399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Targeting of IL-17 and IL-23 Cytokines in Immune-Mediated Diseases.
    Fragoulis GE; Siebert S; McInnes IB
    Annu Rev Med; 2016; 67():337-53. PubMed ID: 26565676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ixekizumab: an anti- IL-17A monoclonal antibody for the treatment of psoriatic arthritis.
    Toussirot E
    Expert Opin Biol Ther; 2018 Jan; 18(1):101-107. PubMed ID: 29187009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of antitumour necrosis factor-α and anti-interleukin-12/23 antibodies in refractory psoriasis and psoriatic arthritis: a long-term case-series observational study.
    Gniadecki R; Bang B; Sand C
    Br J Dermatol; 2016 May; 174(5):1145-6. PubMed ID: 26522308
    [No Abstract]   [Full Text] [Related]  

  • 17. Association of psoriasis/psoriatic arthritis with inflammatory bowel disease influences management strategy.
    Shaw CA; Kole LCS; Elewski BE
    J Eur Acad Dermatol Venereol; 2019 Nov; 33(11):e431-e432. PubMed ID: 31220373
    [No Abstract]   [Full Text] [Related]  

  • 18. Ixekizumab in the treatment of psoriatic arthritis.
    Lespessailles E; Toumi H
    Immunotherapy; 2021 Jan; 13(1):19-33. PubMed ID: 33167745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ustekinumab: The "New Kid on the Block" in the Treatment of Psoriatic Arthritis.
    Torres T; Faria R
    Drug Dev Res; 2015 Dec; 76(8):428-31. PubMed ID: 26372543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ustekinumab associated with flares of psoriatic arthritis.
    Stamell EF; Kutner A; Viola K; Cohen SR
    JAMA Dermatol; 2013 Dec; 149(12):1410-3. PubMed ID: 24132520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.